Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Shenzhen Hepalink Rises 27% in First Trading Session

publication date: May 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shenzhen Hepalink gained as much as 27% from its IPO price in its first trading session, hitting a high of 188 RMB ($27.65). The IPO was priced at 148 RMB ($21.76), which was already a pricey 72 times its 2009 earnings. Hepalink is the world’s leading producer of the blood thinner Heparin. Li Li and Li Tan, the founders of Hepalink, own 72% of the company, a stake that is now worth $7.6 billion. More details...



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors